StockData
Ascentage Pharma Group International logo

Ascentage Pharma Group International (AAPG) shareholders

AAPGNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 29, 2026Score 3/30
$13.14−0.15 (-1.13%)

Close on Nov 17, 2026Market cap $1.23BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.0%
0M of 373M shares
Institutional holders
8
3 new, 2 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of AAPGValueChange% of portfolio
Point72 Asset Management, L.P.13,8410.00%$243.05K−2,2150.00%
Morgan Stanley9190.00%$16.14K+4210.00%
Wells Fargo & Company/Mn2000.00%$3.51KNew0.00%
EverSource Wealth Advisors, LLC240.00%$421–0.00%
UBS Group AG150.00%$263−1090.00%
Royal Bank of Canada60.00%$0–0.00%
BlackRock, Inc.60.00%$105New0.00%
Caitong International Asset Management Co., Ltd10.00%$18New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202680M0.0%3 / 12 / 20M0M
Q1 202670M0.0%0 / 23 / 50M0M
Q4 2025120M0.0%2 / 35 / 30M0M
Q3 2025140M0.0%6 / 34 / 40M0M
Q2 2025120M0.0%9 / 12 / 30M0M
Q1 202560M0.1%6 / 00 / 00M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

3 funds held AAPG in Q4 2025, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of AAPGValue% of fundAs of
Fidelity Nasdaq Composite Index Fund3610.00%$7.26K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Dajun YangChairman and CEO, Director37,742,09110.11%May 22, 2026
Faical MiyaraChief Business Officer––Jun 29, 2026
Yifan ZhaiChief Medical Officer37,742,09110.11%May 22, 2026
Veet MisraChief Financial Officer––Apr 21, 2026
Jin CaoChief Accounting Officer5,4000.00%Apr 20, 2026
Thomas J. KnappSVP/General Counsel362,4440.10%Mar 23, 2026
Shaomeng WangDirector10,053,9432.69%Mar 23, 2026
Ren WeiDirector8,9640.00%Mar 23, 2026
Marc E. LippmanDirector21,1740.01%Mar 23, 2026
David SidranskyDirector10,6410.00%Mar 23, 2026
Marina BozilenkoDirector––Mar 23, 2026
Debra YuDirector––Mar 23, 2026
Simon Dazhong LuDirector41,4570.01%Mar 23, 2026
Changqing YeDirector8,9640.00%Mar 23, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Yifan Zhai
Chief Medical Officer
May 21, 2026Option exercise+92,746––405,280
Yifan Zhai
Chief Medical Officer
May 21, 2026Option exercise+95,575––1,193,569
Dajun Yang
Chairman and CEO, Director
May 21, 2026Option exercise+95,575––1,193,569
Dajun Yang
Chairman and CEO, Director
May 21, 2026Option exercise+92,746––405,280

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-49.8%
From 0M shares
Short volume, 20 days
59.3%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Ascentage Pharma Group International's stock actually held short. Settlement fails (shares not delivered on time) peaked at 5,800 shares on Sep 9, 2026 over the last 90 days.

See a number that looks wrong?